Brad Kahl, MD, is a professor of medicine and director of the lymphoma program at Washington University School of Medicine, St. Louis. Dr. Kahl’s clinical interests involve the care of patients with Hodgkin lymphoma, non-Hodgkin’s lymphoma, and chronic lymphocytic leukemia. His research focuses on the development of new treatments for lymphoma patients, with emphasis on novel agents. He is the principal investigator of numerous clinic trials at Washington University. He is also the Chairman of the Eastern Cooperative Oncology Group Lymphoma Committee. Dr. Kahl also serves as a member of the NCCN CLL Guidelines panel. Dr. Kahl also serves as Director of the new Blood Cancer Center within the Division of Oncology at Washington University School of Medicine.